HIF1A and breast carcinoma: Additional treatment in the HepG2 liver cancer cell line and MCF7 breast cancer cells established the combination of MET and SVA interfered with the ET-1-induced nuclear localisation of HIF-1α, along with PHD2 upregulation, resulting in increased degradation of HIF-1α, reducing angiogenesis [38].